Results 121 to 130 of about 110,790 (277)

The activation of human complement component C5 by a fluid phase C5 convertase.

Journal of Biological Chemistry, 1983
Complement component C5 is converted to C5a and C5b by the cobra venom factor-dependent C3/C5 convertase CVF,Bb (EC 3.4.21.47). The C5 convertase produces selective proteolytic cleavage of an arginyl-leucine peptide bond at positions 74-75 in the alpha chain of C5.
R G, DiScipio, C A, Smith, H J, Muller-Eberhard, T E, Hugli   +3 more
openaire   +2 more sources

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

American Journal of Hematology, EarlyView.
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth, Christopher J. Patriquin, Jeff Szer, Louis Terriou, Ami S. Patel, Jesse Metzger, Philippe Gustovic, Jun‐ichi Nishimura, Robert A. Brodsky   +8 more
wiley   +1 more source

K3 surfaces with $\mathbb{Z}_2^2$ symplectic action

, 2018
Let $G$ be a finite abelian group which acts symplectically on a K3 surface. The N\'eron-Severi lattice of the projective K3 surfaces admitting $G$ symplectic action and with minimal Picard number is computed by Garbagnati and Sarti.
Schaffler, Luca
core   +1 more source

Terminal complement without C5 convertase? [PDF]

Blood, 2021
openaire   +2 more sources

A Transcriptome Array-Based Approach to Link SGLT-2 and Intrarenal Complement C5 Synthesis in Diabetic Nephropathy. [PDF]

Int J Mol Sci, 2023
Korsten P, Tampe B.
europepmc   +1 more source

Activation of Complement Component C5 [PDF]

Journal of Biological Chemistry, 2008
Nenoo Rawal, Rema Rajagopalan, Veena P. Salvi   +2 more
openaire   +1 more source

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with Covid-19: an open-label randomized controlled trial [PDF]

Respir Res, 2022
De Leeuw E, Damme KFV, Declercq J, Bosteels C, Maes B, Tavernier SJ, Detalle L, Smart T, Glatt S, Debeuf N, Deckers J, Lameire S, Vandecasteele SJ, De Neve N, Demedts IK, Govaerts E, Knoop C, Vanhove K, Moutschen M, Terryn W, Depuydt P, Braeckel EV, Haerynck F, Hendrickx TC, Parrein V, Lalla M, Brittain C, Lambrecht BN.   +27 more
europepmc   +2 more sources

Complement C5 is a novel biomarker for liver metastasis of colorectal cancer. [PDF]

J Gastrointest Oncol, 2022
Chang H, Jin L, Xie P, Zhang B, Yu M, Li H, Liu S, Yan J, Zhou B, Li X, Xu Y, Xiao Y, Ye Q, Guo L.   +13 more
europepmc   +1 more source

Intraocular complement activation is independent of systemic complement activation and is related to macular vascular remodelling in retinal vein occlusion

BMC Ophthalmology
Background Retinal vein occlusion (RVO) is a major cause of vision loss. The pathogenesis remains poorly defined although inflammation is known to play a critical role.
Hengwei Liu, Yufan Zhou, Jinyan Qi, Shengnan Liang, Tingting Guo, Juan Chen, Huanhuan Tan, Jie Wang, Heping Xu, Zhongping Chen   +9 more
doaj   +1 more source

Immunopathology of terminal complement activation and complement C5 blockade creating a pro-survival and organ-protective phenotype in trauma. [PDF]

Br J Pharmacol, 2023
Yang Z, Nunn MA, Le TD, Simovic MO, Edsall PR, Liu B, Barr JL, Lund BJ, Hill-Pryor CD, Pusateri AE, Cancio LC, Li Y.   +11 more
europepmc   +1 more source